2025 was a pivotal year for cardiovascular medicine, marked by groundbreaking research and shifts in treatment strategies. The landscape of cardiology underwent significant transformations, impacting how we assess risk and treat heart conditions.
One of the most notable changes occurred in interventional cardiology. A major area of focus was aspirin, with several long-held beliefs being challenged by new findings.
Research indicated that the routine use of aspirin may not provide the expected benefits and could even increase risks. The data suggested that lifelong aspirin use was based on outdated evidence, and newer antiplatelet therapies, like clopidogrel, may become the preferred choice.
But here's where it gets controversial... Some clinical trials involving aspirin were halted early due to an excess of deaths, prompting doctors to rethink their prescribing habits. It was found that aspirin, when used with anticoagulation therapy, did not reduce the risk of stent thrombosis (a major reason for aspirin use after stent implantation) and actually increased the risk of death from any cause by 72%.
In addition to aspirin, there was a push for single-pill combinations (SPCs) or fixed-dose combinations (FDCs) as the first-line treatment for hypertension.
Australian researchers also made strides in CRISPR research, with the first human trial successfully using gene editing to manage cholesterol. This single injection of gene-editing tools led to significant reductions in both cholesterol and triglycerides, offering a potential breakthrough for mixed lipid disorder management.
Speaking of lipids, the European Society of Cardiology and the European Atherosclerosis Society released new international recommendations for dyslipidaemia management. These guidelines proposed a more aggressive approach to lipid-lowering regimens, moving away from the traditional "low and slow" approach. The guidelines also highlighted the importance of using Lp(a) for heart disease prevention, a previously overlooked cardiovascular risk factor. Routine screening could potentially prevent numerous heart attacks, strokes, and early deaths.
And this is the part most people miss... The annual American Heart Association scientific sessions featured multiple studies on PCSK9 inhibitors for cholesterol management, including a large trial of an oral version of the injectable medication. Studies showed that combining PCSK9 inhibitors with statins offered additional protection, reducing the risk of cardiovascular death, heart attack, or ischemic stroke by over a quarter.
Cardiologists from Italy, Germany, and the US noted that interventional cardiology in 2025 was defined by clinical trials that reshaped daily practice, refined procedural strategies, and clarified long-term expectations for percutaneous therapies. These publications refined antiplatelet management after PCI, clarified the optimal timing of multivessel revascularization in ST-elevation myocardial infarction, reinforced the value of imaging and physiology in complex PCI, and extended our understanding of transcatheter aortic valve implantation (TAVI) durability in low-risk patients.
What do you think about these changes? Do you agree with the shift away from aspirin? Share your thoughts in the comments!
